Home › Leucemia linfatica cronica › Illinois
Studi clinici su Leucemia linfatica cronica nello stato di Illinois
17 studi su Leucemia linfatica cronica cercano partecipanti presso sedi nello stato di Illinois.
Città nello stato di Illinois
- Chicago14 studi
- Evanston4 studi
- Springfield4 studi
- Waukegan4 studi
- Danville3 studi
- Champaign3 studi
- Decatur3 studi
- Charleston3 studi
Testo ufficiale dello studio (inglese)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- e altri 27
In reclutamentoFase 3
Età 65 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- e altri 54
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Rush-Copley Medical Center, Aurora
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- e altri 28
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Northwestern University, Chicago
- Illinois Cancer Specialists (Niles) Usor, Niles
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT06943872A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Northwestern University, Chicago
- Midwestern Regional Medical Center, Zion
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07277231A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- University of Chicago Medical Center, Chicago
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT06973187Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Chicago, Zion
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT04588922A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- The David and Etta Jonas Center for Cellular Therapy, Chicago
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT06528301ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Orchard Healthcare Research, Skokie
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT07342478A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Northwestern University, Chicago
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 lug 2026 · NCT05131022Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
In reclutamentoFase 1
Età 13 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT04771572The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Illinois at Chicago Cancer Center, Chicago
In reclutamentoFase 1/2
Età da 12 a 95 · Tutti i sessi · Aggiornato il 15 apr 2026 · NCT04329728A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Springfield Clinic - First /ID# 270145, Springfield
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 apr 2026 · NCT06428019A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- The University of Chicago Medical Center, Chicago
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 mar 2026 · NCT04830137A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Northwestern University, Chicago
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 mar 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Northwestern University, Chicago
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 mar 2026 · NCT06876649AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Northwestern Memorial Hospital, Chicago
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 dic 2025 · NCT05602363Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.